This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Stephen Elliman
Chief Scientific Officer at Orbsen Therapeutics, USA


Dr Stephen Elliman  is Orbsen’s Founding Scientist and Chief Scientific Officer. Steve’s PhD focused on describing and defining human stromal cell (SC) populations at UCL in London. He moved to develop SC as a discovery platform at Novartis here in Boston and then obtained a Marie Curie Fellowship to transfer SC technologies to the National University of Ireland in Galway. Steve co-founded Orbsen to identify novel SC surface markers to enable SC purification isolation for therapeutic use. Orbsen has 4 early phase clinical trials assessing the safety & efficacy of ORBCEL in patients with ARDS, autoimmune diseases and kidney disease.

Agenda Sessions

  • Pre-clinical and Early Clinical Development of ORBCEL Immunotherapy